Molecular Partners (NASDAQ:MOLN) Shares Up 6.4% – Time to Buy?

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) rose 6.4% during trading on Monday . The company traded as high as $4.25 and last traded at $4.18. Approximately 6,088 shares were traded during trading, an increase of 117% from the average daily volume of 2,802 shares. The stock had previously closed at $3.93.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MOLN. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Stock Performance

The firm has a market cap of $161.12 million, a P/E ratio of -2.06 and a beta of 1.08. The firm has a 50 day simple moving average of $3.97 and a 200 day simple moving average of $4.23.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). Sell-side analysts predict that Molecular Partners AG Sponsored ADR will post -1.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors and hedge funds own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.